Wunderlich F T, Wildner H, Rajewsky K, Edenhofer F
Institute for Genetics, University of Cologne, Weyertal 121, D-50931 Cologne, Germany.
Nucleic Acids Res. 2001 May 15;29(10):E47. doi: 10.1093/nar/29.10.e47.
We have developed a novel inducible Cre mutant with enhanced recombinase activity to mediate genetic switching events. The protein, designated CrePR, is composed of a new Cre mutant at the N-terminus followed by the ligand-binding domain (LBD) of the progesterone receptor (PR). The response to low doses of inducer is significantly enhanced by elongating the C-terminus of the PR LBD from amino acid 891 to 914. The mutant Cre lacks the first 18 amino acids and contains a Val-->Ala substitution at position 336, thereby destroying a cryptic splice donor at the 3'-end of CRE: The latter mutation reduces unwanted background recombinase activity in the absence of the synthetic ligand RU486 by a factor of at least 10 to an almost undetectable level. Thus, the recombinase activity turns out to be inducible by a factor of >200. We expect CrePR to serve as a valuable tool for conditional expression of genes both in vitro and in vivo.
我们开发了一种具有增强重组酶活性的新型诱导型Cre突变体,用于介导基因转换事件。该蛋白命名为CrePR,由N端的一种新型Cre突变体和孕酮受体(PR)的配体结合域(LBD)组成。通过将PR LBD的C端从氨基酸891延长至914,对低剂量诱导剂的反应显著增强。突变型Cre缺少前18个氨基酸,并且在第336位含有Val→Ala替换,从而破坏了CRE 3'端的一个隐蔽剪接供体:后一种突变将在没有合成配体RU486的情况下不需要的背景重组酶活性降低了至少10倍,降至几乎检测不到的水平。因此,重组酶活性被诱导了>200倍。我们期望CrePR成为体外和体内基因条件表达的有价值工具。